Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Watch CTHE 1.12 makin a move. Read about this one before holding though. Reverse merge. Check the filings.
CTHE-Here is some info on the company that will take over. Notice the S-8.
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=xcor#getFilings
CTHE reverse merger. PREM14C filed Friday at 1744.
http://www.sec.gov/Archives/edgar/data/752789/000095014807000196/v32940aprem14c.htm
I think you meant .06 LOL
Someone is accumulating some. Interesting, could be chinawatcher.
NBS (NEOI) closed up 36%.
WRII-.012 15-12G today
ONMC-.006 15-12G today.
More shells than you can shake a stick at.
http://www.shellstockreview.com/ssr-Home.html
Man you better get some sleep, market opens 4.5 hours. Your as bad as me. LOL
SHPI-.76
Specialized Health Products Reports Second Quarter 2007 Financial Results
Expanding Net Income, Positive Cash Flow, Sustained Revenue Growth
Specialized Health Products International, Inc., (“Specialized Health Products”) (OTCBB: SHPI), a leading developer and manufacturer of proprietary safety medical products, today announced financial results for the three and six month periods ended June 30, 2007.
Highlights for Q2-2007:
Fifth consecutive profitable quarter, earned net income of $454,000 in Q2-2007 compared to $228,000 in Q2-2006, representing 99% growth;
Sustained revenue growth, increased revenue 30% year-over-year to $4.4 million in Q2-2007, from $3.4 million in Q2-2006;
Advanced manufactured product sales 31% to $3.3 million in Q2-2007, from $2.5 million in Q2-2006;
Maintained high gross profit margin of 65%.
“Specialized Health Products is proving to be a classic small cap growth story,” commented Jeff Soinski, President and Chief Executive Officer of Specialized Health Products. “We continue to deliver strong revenue growth. We are consistently generating net income that is growing at a higher rate than sales. And, we are now beginning to generate positive cash flow. Based upon this continued strong financial performance, we believe we are squarely on target to achieve the goals and objectives for 2007 that we defined at the beginning of the year.”
Financial Results for Q2-2007
Total revenue for the three month period ended June 30, 2007 amounted to $4.4 million, representing an increase of 30% over the $3.4 million posted in the year earlier period.
Product sales for the quarter ended June 30, 2007 advanced 31% year-over-year to $3.3 million, compared to $2.5 million in Q2-2006. In the same time frame, royalty income grew 92% to $1.0 million in Q2-2007, from $527,000 in Q2-2006. Technology fees and licensing revenues were equal at $49,000 in the two comparable periods. Development fees and related services declined 95% to $14,000 in Q2-2007, compared to $252,000 in Q2-2006.
The primary drivers of product sales growth were increased market penetration of the Company’s leading safety Huber needle products, and increased OEM product sales to Bard Access Systems and Covidien. The increase in royalty income is primarily attributable to the growth of licensed products to BD Medical, including the Vacutainer® Push Button Blood Collection Set and the Integra™ Syringe. The decrease in development fees and related services reflects the Company’s continuing transition to an emphasis on manufactured product sales in its revenue mix and the maturation of funded development projects.
Gross profit in Q2-2007 was $2.8 million, representing a 30% increase over the $2.2 million recorded in Q2-2006. Gross profit margin was 65% during both comparable periods.
Operating expenses were $2.4 million in Q2-2007, representing a 26% increase compared to the $1.9 million realized in Q2-2006. The primary drivers of increased expenses are increased personnel costs required to support significantly higher product sales volumes, and incremental costs associated with operating a combined entity following Specialized Health Products’ merger with The Med-Design Corporation on June 2, 2006.
Net income increased 99% to $454,000 in Q2-2007, from $228,000 in Q2-2006. Earnings per diluted share (“EPS”) were $0.01 for Q2-2007, compared to $0.00 for Q2-2006.
Excluding amortization of stock-based compensation (a non-cash expense), the Company would have achieved non-GAAP net income of $831,000 and EPS of $0.01 in Q2-2007, representing a non-GAAP net income margin of 19%.
During Q2-2007, the Company’s cash, cash equivalents and available-for-sale securities increased $298,000 on a sequential quarter basis. At June 30, 2007, Specialized Health Products had cash, cash equivalents and available-for-sale securities totaling $6.9 million.
Financial Results for Six Months Ended June 30, 2007
Total revenue for the first six months of 2007 increased 59% to $8.6 million, from $5.4 million in the first six months of 2006.
Product sales advanced 68% to $6.6 million in the first six months of 2007, from $3.9 million in the first six months of 2006. Royalty income increased 91% to $1.8 million, from $962,000 in the year-earlier period. Technology fees and licensing revenues were equal at $98,000 in the two six-month periods. Development fees and related services declined 91% to $37,333 in the first six months of 2007, from $406,000 in the first half of 2006.
Gross profit margin in the first six months of 2007 was 66%; an improvement over the 64% recorded in the first half of 2006. The improvement was largely attributable to the sharp increase in royalty income, which has little or no cost of revenue, as well as the dramatic decrease in development fees and related services, which have a relatively high cost of revenue.
Operating expenses increased 33% to approximately $5.0 million for the six-month period ended June 30, 2007. The primary drivers of increased expenses are increased personnel costs required to support significantly higher product sales volumes, and incremental costs associated with operating a combined entity following Specialized Health Products’ merger with The Med-Design Corporation.
Net income for the first six months of 2007 was $758,000. This represents an improvement of 340% compared to a net loss of $315,000 in the first six months of 2006. Earnings per share were $0.01 for the first six months of 2007, compared to a loss of ($0.01) for the same period in 2006.
Excluding amortization of stock-based compensation, the Company would have achieved non-GAAP net income of $1.5 million and EPS of $0.02 for the first six months of 2007, representing a 17% non-GAAP net income margin.
Net cash of $687,000 was provided by operations during the first six months of 2007, an increase of approximately $1.5 million over the $778,000 of net cash used during the same period in 2006.
Financial Results for Trailing Twelve Months Ended June 30, 2007
For the trailing twelve months (“TTM”) ended June 30, 2007, total revenue increased 82% to $16.5 million, from $9.1 million in the trailing twelve months ended June 30, 2006.
For the TTM ended June 30, 2007, operating income increased to $1.3 million, representing a $3.6 million improvement compared to an operating loss of $2.3 million in the year earlier period.
For the TTM ended June 30, 2007, net income and EPS were $1.5 million and $0.02, respectively, compared to a loss of $2.4 million and ($0.06), respectively, in the TTM ended June 30, 2006. This represents an improvement of $3.8 million and $0.08 per share, respectively, in the 2007 period.
Excluding amortization of stock-based compensation, the Company would have achieved non-GAAP net income of $2.9 million and EPS of $0.04 for the TTM ended June 30, 2007, representing a non-GAAP net income margin of 17%.
Non-GAAP Measures of Financial Performance
To supplement the Company’s consolidated financial statements presented in accordance with generally accepted accounting principles, or GAAP, Specialized Health Products uses non-GAAP measures of net income and non-GAAP earnings per diluted share.
These non-GAAP measures are not in accordance with, or an alternative for, measures prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with Specialized Health Products’ results of operations as determined in accordance with GAAP. These measures should only be used to evaluate Specialized Health Products’ results of operations in conjunction with the corresponding GAAP measures.
Reconciliation to the nearest GAAP measure of all non-GAAP measures included in this press release can be found in the tables included in this press release.
Non-GAAP measures are provided to enhance investors’ overall understanding of the Company’s current financial performance and the company’s prospects for the future. Specifically, the Company believes the non-GAAP measures provide useful information to both management and investors by excluding certain non-cash expenses. The sole adjustment to the Company’s GAAP financial statement presentation is the add-back to net income of the amount represented by amortization of stock-based compensation. Stock-based compensation expense consists entirely of the expense related to the issuance of restricted stock to Directors and employees of Specialized Health Products under Statement of Financial Accounting Standards No. 123 (revised 2004), “Share-Based Payment.” Specialized Health Products excludes stock-based compensation expenses from its non-GAAP income and EPS measures primarily because they are non-cash expenses that the Company does not believe are reflective of ongoing operating results.
In determining non-GAAP net income and EPS for the Company, an incremental tax representing an estimated amount for alternative minimum tax was deducted from the incremental income resulting from the add-back of stock based compensation expense. Company management believes there are sufficient NOL assets to mitigate any additional state or federal income taxes.
Conference Call
The Company will host a conference call at 4:30 p.m. EDT on Wednesday, August 8, 2007, to discuss earnings for the 2007 fiscal second quarter ended June 30, 2007. To participate in the conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: (800) 230-1766. International callers should dial (612) 332-0228. This conference call will also be broadcast live over the Internet and can be accessed through a link on the Company’s website at www.shpi.com. To listen to the live call, please go to the Specialized Health Products website at least fifteen minutes prior to the start of the call to register, download, and install any necessary audio software. For those unable to participate during the live broadcast, a replay will be available by 8:00 p.m. EDT on August 8, 2007 through August 15, 2007 at (800) 475-6701 or (320) 365-3844, using the access code 882391. The replay will also be available shortly after the call on the Specialized Health Products website.
About Specialized Health Products International, Inc.
Specialized Health Products International, Inc. is a leading developer, manufacturer and marketer of proprietary disposable medical products for clinician and patient safety. Specialized Health Products has developed multiple safety needle products based upon a broad intellectual property portfolio that applies to virtually all medical needles used today. Specialized Health Products is a market leader in safety Huber needles, with four complementary product offerings. The Company has licensed or supplies other products to leading global healthcare companies, including Covidien, Bard Access Systems, and BD Medical. For more information about Specialized Health Products, visit the Company’s website at www.shpi.com.
Forward-Looking Statements
The statements contained in this press release regarding goals and objectives for 2007 and other statements that are not historical fact, are forward-looking statements and are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to risks and uncertainties. We wish to advise readers that a number of important factors could cause actual results to differ materially from historical results or those anticipated in such forward-looking statements. These factors include, but are not limited to the inability to locate or consummate desired acquisitions, unforeseen delays in manufacturing our products, unforeseen demands upon our cash and cash equivalents and the demand for our products being less than anticipated. These and other factors that could cause actual results to differ materially from those anticipated are discussed in more detail in our filings with the Securities and Exchange Commission, including our annual report on Form 10-KSB for the fiscal year ended December 31, 2006. These forward-looking statements speak only as of the date on which such statements are made, and we undertake no obligation to update such statements to reflect events or circumstances arising after such date.
National Energy Group, Inc. Reports Fiscal 2007 Second Quarter Results
DALLAS, Aug. 8 /PRNewswire-FirstCall/ -- National Energy Group, Inc. (OTC Bulletin Board: NEGI) today announced results for the three and six month periods ended June 30, 2007.
Results of Operations
The Company reported total revenues of $0.6 million for the three month period ended June 30, 2007 compared to $17.7 million for the three month period ended June 30, 2006. Revenues for the six month period ended June 30, 2007 were $1.4 million compared to $36.4 million in the same period in 2006. Net loss was $29,000 for the three month period ended June 30, 2007 compared to net income of $7.1 million for the comparable period in 2006. Net loss for the six month period ended June 30, 2007 was $0.3 million as compared to net income of $13.0 million for the comparable period in 2006.
On November 21 2006, the Company completed the sale of its non-controlling 50% membership interest in NEG Holding LLC to NEG Oil & Gas LLC, paid its debt obligations in full, terminated its management agreements with NEG Operating LLC, National Onshore LP, and National Offshore LP and terminated the employment of the majority of its employees. Subsequent to November 21, 2006, the Company has no business operations and its principal assets consist of cash and short-term investment balances, which aggregated $48.2 million at June 30, 2007.
The Company's results of operations for the three and six month periods ended June 30, 2007 are more fully described in the unaudited financial statements and the accompanying notes and other information included in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2007. Investors are urged to review the Form 10-Q and the Company's Annual Report Form 10-K for the year ending December 31, 2006 filed with the SEC on March 6, 2007, including the risk factors applicable to the Company.
The Company
Subsequent to November 21, 2006, the Company has no business operations and its principal assets consist of cash and short-term investment balances, which approximated $48.2 million at June 30, 2007. As a result, the Company is a shell company as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended. The Company's Board of Directors intends to consider the appropriate application of the Company's remaining cash and short-term investment balances, including but not limited to the possible acquisition of producing oil and gas properties and related businesses and assets or the equity in another entity which owns such properties, businesses and assets, the distribution of some or all of our assets to shareholders, or our liquidation and dissolution. There can be no assurance the Company's Board of Directors will authorize any such transaction.
Forward Looking Statements
This press release includes 'forward-looking statements' within the meaning of various provisions of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. The words 'anticipate,' 'expect,' 'estimate,' 'predict,' 'believe,' and similar expressions and variations thereof are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this press release that address activities, events, or developments that we expect or anticipate will or may occur in the future relating to the operations of National Energy Group, Inc., our business strategies, goals, plans, references to future success, references to intentions as to future matters and other such matters are forward-looking statements and include statements regarding the interest, belief or current expectations of our management, directors, or officers regarding such matters. These statements are based on certain assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions and expected future developments as well as other factors we believe are appropriate under the circumstances. However, whether actual results and developments will conform with our expectations and predictions is subject to a number of risks and uncertainties, including the risk factors (see Item 1A--Risk Factors) discussed in our Annual Report on Form 10-K for the year ended December 31, 2006, the opportunities (or lack thereof) that may be presented to and pursued by us, competitive actions by other companies, changes in laws or regulations, and other factors, many of which are beyond our control. Consequently, all of the forward-looking statements made in this document are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated will be realized or, even if substantially realized, that they will have the expected consequences to or effects on our Company or our business or operations. Such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements.
SOURCE National Energy Group, Inc.
Source: PR Newswire (August 8, 2007 - 4:17 PM EST)
News by QuoteMedia
www.quotemedia.com
TRCI-3.30
Technology Research Corporation Reports First Quarter Financial Results Reflecting Improved Profitability on Lower Revenues
Technology Research Corporation (“TRC”), (NASDAQ:TRCI), today announced revenues and earnings for its first fiscal quarter ended June 30, 2007.
Revenues were $9.7 million, a decrease of $1.0 million or 9% from the revenues reported in the same quarter last year. Net income for the first fiscal quarter ended June 30, 2007 was $483 thousand compared with net income of $20 thousand for the fiscal quarter ended June 30, 2006. Diluted net income is $.08 per share for the current quarter compared with diluted net income of $.00 per share for the same quarter last year.
Orders for the first quarter were $9.4 million, an increase of $1.6 million over the first quarter of fiscal 2007. Military orders were $3.1 million, an increase of $1.9 million over the first quarter of the previous year and Commercial orders were $6.3 million, a decrease of $.3 million from the first quarter of the prior year. Orders received from room air conditioner customers decreased $1.6 million from the first quarter of last year.
Owen Farren, President & CEO, said, “The first quarter results are due to higher revenues than we had planned on and reflect the progress that we have made in the first quarter on the previously reported cost and efficiency operational initiatives. Our systems enhancements and newly developed processes have improved the quality and responsiveness of our business decisions and allowed the Company to operate more efficiently during the quarter despite the 12% reduction in force that took place at the end of March. While we have made many operational changes, we are steadfastly pursuing our long term strategies and we continue to vigorously defend our patented intellectual property for the room air conditioner market.”
Farren continued, “The increase in military bookings announced over the past two quarters and the quicker delivery requirements sought by our military customers resulted in the 41% growth in military revenues during the current quarter compared with the first quarter of fiscal 2007. The 6% increase in gross profit percentage from 23% in fiscal 2007 to 29% in the current quarter is primarily due to product mix and TRC’s decision to focus on its efforts on developing more value added and profitable business with our customers that create greater shareholder value.”
Mr. Farren concluded, “As part of our focus on improving shareholder value, we have undertaken initiatives to improve asset management. To this end, both inventory turns and our days sales outstanding have improved in the first quarter compared with the fourth quarter of fiscal 2007. TRC has also paid down $1.0 million of debt in the first quarter leaving $2.0 million of remaining debt. The Company’s balance sheet remains strong.”
The first quarter dividend of $.02 per share was paid on July 20, 2007 to shareholders of record on June 29, 2007.
TRC is an internationally recognized leader in electrical safety products that prevent electrocution and electrical fires and protect against serious injury from electrical shock. Based on its core technology in ground fault sensing, products are designed to meet the needs of the consumer, commercial and industrial markets worldwide. The Company also supplies power monitors and control equipment to the United States Military and its prime contractors.
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: Some of the statements in this report constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 and the Securities Exchange Act of 1934. These statements are related to future events, other future financial performance or business strategies, and may be identified by terminology such as "may," "will," "should," "expects," "scheduled," "plans," "intends," "anticipates," "believes," "estimates," "potential," or "continue," or the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events as well as results may differ materially. In evaluating these statements, you should specifically consider the factors described throughout this report. We cannot be assured that future results, levels of activity, performance or goals will be achieved.
SLGLF-.082
High grade gold disclosed during Nolan Lode Exploration Program
High grade trend appears to be developing
SILVERADO - OTCBB: SLGLF/Frankfurt: SLGL/Berlin: SLGL
FAIRBANKS, AK, and VANCOUVER, Aug. 8 /PRNewswire-FirstCall/ - Silverado announces that backhoe trenching during the continued exploration of the five-mile long Solomon Shear zone on its Nolan Gold Mine located 280 miles North of Fairbanks, Alaska, has disclosed a 16.4 foot (5 m) continuous chip sample grading 5.22 ounces per ton (179 grams) gold, and 8.74% antimony by ore assay. Due to the exceptionally high content of gold assayed, a second sample was successfully re-assayed at the ALS Chemex Lab confirming this high value.
In addition to the high gold assay found in Trench H, high antimony values were also found. Significant gold values were found in all of H, G and J Trenches. The antimony values reached as high as 30%. These high antimony values are consistent with the previous work in this vicinity where sampling showed antimony assays as high as 46% (see press release January 29, 2007).
Solomon Shear is a highly mineralized gold-bearing system that extends over five miles on Silverado's Nolan property. It has been the focus of Silverado's extensive exploration program, which includes geophysical and geochemical surveys in addition to the trenching program. All of Silverado's 'downstream' placer gold recoveries indicate likely sources higher in the Solomon Shear system. The company is just in the beginning stage of exploring these possible source areas.
Silverado Gold Mines is very pleased with these results and we continue to expand on our knowledge of this discovery. Old time miners and Silverado combined have removed more than 140,000 ounces of gold nuggets and dust from the lower benches of Smith Dome and below Solomon's Shear. Our 2006 trench and drill results confirmed the existence of high-grade gold-antimony-quartz veins in the Solomon Shear. Our highest assay reading from 2006 was 0.83 ounces per ton (see press release January 22, 2007). Now, we are encountering suspected source materials that have assayed considerably higher than those from 2006. This recently discovered high-grade area is under current exploration by further trenching and an extensive drilling program. This drilling, using our recently purchased diamond drill, will begin shortly and continue as long as weather permits.
In June and July 2007, Silverado Gold Mines conducted backhoe trenching on its Nolan Creek property, totaling 328m (1076.12ft), to further investigate the gold bearing antimony-quartz vein systems previously identified in 2006 (see press releases from July 16, 2007, January 29, 2007 and January 22, 2007). A total of 107 combined select chip and continuous chip rock samples were collected during the trenching program and submitted to ALS Chemex in Fairbanks for analysis. To date, Silverado Gold Mines has received the assays for three of the four trenches.
Trench G extends over 72.5m (237.86ft) and is located 25 meters northeast of Trench F (see Fig. 1 - http://www.silverado.com/august082007/figure1.htm). A total of 18 combined select chip and continuous chip rock samples were collected during the trenching program. Sample interval 50-55m (16.4 feet) contains 4.31% antimony (Sb). A select sample of an antimony vein from within this interval assayed 24.60% (see Table 1).
Table 1: Trench G assay results greater than 0.3 g/t Gold or 0.15%
Antimony.
-------------------------------------------------------------------------
Trench G - 72.5m
-------------------------------------------------------------------------
Sample Sample Sample Sample Gold Gold Anti-
grams/tonne Toz/short mony
Number Interval Width Type (metric) ton %
-------------------------------------------------------------------------
Continuous
07G11 50-55m 5m chip 0.30 0.01 4.31
-------------------------------------------------------------------------
53.50-
07G17N 53.52m 0.02m Select chip 1.73 0.05 24.60
-------------------------------------------------------------------------
53.50-
07G18S 53.58m 0.08m Select chip 2.71 0.08 0.15
-------------------------------------------------------------------------
Trench H, 25m (82.02ft) in length, is located 43 meters northeast of Trench F (see Fig. 1 - http://www.silverado.com/august082007/figure1.htm). A total of 6 combined select chip and continuous chip rock samples were collected during the trenching program. Sample interval 5-10m contains 2.62% antimony (Sb) and 0.02 troy ounces of gold per ton. Sample interval 10-15m was assayed with 5.22 troy ounces per ton of gold and 8.74% antimony (see Table 2). This interval was re-assayed for gold by ALS Chemex and yielded 5.04 troy ounces per ton of gold. A select sample of an antimony vein from within this interval was assayed with 0.11 troy ounces per ton of gold and more than 1% Sb (total Sb analysis is pending). Intervals 5-10 and 10-15 are currently being further investigated by Silverado exploration geologists as the data obtained to date appears to indicate the possibility of a high grade trend.
Table 2: Trench H assay results greater than 0.3 g/t Gold or 1% Antimony.
-------------------------------------------------------------------------
Trench H - 25m
-------------------------------------------------------------------------
Sample Sample Sample Sample Gold Gold Anti-
grams/tonne Toz/short mony
Number Interval Width Type (metric) ton %
-------------------------------------------------------------------------
Continuous
07H2 5-10m 5m chip 0.77 0.02 2.62
-------------------------------------------------------------------------
Continuous
07H3 10-15m 5m chip 179.00 5.22 8.74
-------------------------------------------------------------------------
(greater
10.30- than)
07H6 10.32m 0.02m Select chip 3.82 0.11 1%
-------------------------------------------------------------------------
Trench J (Workman's Bench Trench), 38m (124.7ft) in length, was dug south of Smith Creek, in the old Workman's Bench pit, located within in the south-westward extension of the Solomon Shear trend. This trench exposed the largest antimony veins discovered in the area to date, with widths up to 24 cm (9.8 inch). A total of 15 continuous chip rock samples (2.5m composite) were collected during the trenching program. Out of these 15 samples, 7 show antimony values from 1.7% to 30.3% (see Table 3). 5 samples show values higher than 0.01 ounces per ton gold, ranging from 0.01 to 0.12 ounces per ton gold.
Table 3: Trench J (Workman's Bench) assay results greater than 0.04 g/t
Gold or 1% Antimony.
-------------------------------------------------------------------------
Trench J (Workman's Bench) - 38m
-------------------------------------------------------------------------
Sample Sample Sample Sample Gold Gold Anti-
grams/tonne Toz/short mony
Number Interval Width Type (metric) ton %
-------------------------------------------------------------------------
Continuous
4WT 7.5-10m 2.5m chip 0.04 0.00 1.7
-------------------------------------------------------------------------
Continuous
10WT 22.5-25m 2.5m chip 0.14 0.00 30.3
-------------------------------------------------------------------------
Continuous
11WT 25-27.5m 2.5m chip 0.22 0.01 1.72
-------------------------------------------------------------------------
Continuous
12WT 27.5-30m 2.5m chip 1.27 0.04 11.7
-------------------------------------------------------------------------
Continuous
13WT 30-32.5m 2.5m chip 4.17 0.12 29.3
-------------------------------------------------------------------------
Continuous
14WT 32.5m-35m 2.5m chip 0.55 0.02 2.56
-------------------------------------------------------------------------
Continuous
15WT 35-38m 3m chip 0.54 0.02 14.05
-------------------------------------------------------------------------
This press release was prepared by Dr. Karsten Eden, Certified Professional Geologist; who is a qualified person as defined under the standards of Canadian National Instrument policy 43-101.
About Silverado:
Silverado is an international company focused on Gold and a new environmentally friendly Fuel Technology. Silverado has gold properties located throughout Alaska, which include the 100% owned Nolan Placer Gold Mine. Silverado is also entering the construction phase of an environmentally friendly low cost strategic fuel demonstration facility. Silverado's Green Fuel will be produced from low-rank coal and processed into an environmentally friendly oil substitute. Silverado Green Fuel Inc. is a wholly owned subsidiary of its publicly traded parent, Silverado Gold Mines Ltd. For more information about Silverado Green Fuel Inc., please visit http://www.silveradogreenfuel.com/ and the parent public corporation, http://www.silverado.com/.
This Press Release may contain, in addition to historical information, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on management's expectations and beliefs, and involve risks and uncertainties. These statements may involve known and unknown risks and uncertainties and other factors that may cause the actual results to be materially different from the results implied herein. Readers are cautioned not to place undue reliance on the forward-looking statements made in this Press Release.
CONTACT: SILVERADO GOLD MINES LTD., Mailing Address, 505 1111 W. Georgia Street, Vancouver, B.C., V6E 4M3, CA, Toll Free: (800) 665-4646 or (604) 689-1535, Fax: (604) 682-3519, pr@silverado.com, http://www.silverado.com; Field Address, 3180 Peger Rd, Ste 270, Fairbanks, AK, 99709-5485, USA
SOURCE Silverado Gold Mines Ltd.
Source: PR Newswire (August 8, 2007 - 5:29 PM EST)
News by QuoteMedia
www.quotemedia.com
NEOI-.50
NeoStem Announces Approval for Listing on American Stock Exchange Under Ticker Symbols NBS and NBS.U Starting Thursday August 9, 2007
Concurrent with the Listing, NeoStem Announces Closing of a Public Offering for Over $5 Million and Completes a 1-for-10 Reverse Stock Split
NeoStem, Inc. (OTCBB:NEOI), the first company to specialize in the collection, processing and long term storage of stem cells from healthy adults for personal use in times of critical medical need, today announces its common stock and units have been approved to be listed on the American Stock Exchange under the ticker symbols—NBS and NBS.U—and will start trading August 9, 2007. The listing followed the completion of a public-offering in excess of $5 million and a one-for-ten reverse stock split.
The listing on the American Stock Exchange is consistent with the Company’s strategic mission to attract institutional investors and to provide long-term value for its shareholders.
“We are extremely proud of our recent achievements and of surpassing yet another milestone for the benefit of our shareholders,” said Robin Smith, M.D., Chairman and Chief Executive Officer of NeoStem. “It is an honor to be listed on the American Stock Exchange and to enjoy all the benefits of its long and storied history. We believe these recent developments will be major catalysts as we move forward into a position of leadership in the burgeoning market for stem cell therapies and services.”
The closing of this offering is the latest validation of NeoStem’s high-growth business model focused on developing next generation services and therapies that have the potential to help millions of health-conscious individuals. The total offering comprises units at a price of $5 per unit. Each unit consists of one share of common stock and one-half a Class A warrant to purchase one-half a share of common stock. Thus, 1,000 units consist of 1,000 shares and warrants to purchase 500 shares of common stock.
The Underwriter for the offering was Mercer Capital Ltd., members of the National Association of Securities Dealers, Inc.
NeoStem’s common stock, units and Class A warrants have been accepted for listing on the American Stock Exchange under the symbols “NBS”, “NBS.U”, and “NBS.WS” respectively, effective upon consummation of the initial closing of the offering. The CUSIP for the Common Stock is 640650305, the CUSIP for the Units is 640650206, and the CUSIP for the Warrants is 640650115.
NeoStem’s first-to-market competitive advantage uniquely positions the Company to capitalize on the hundreds of adult stem cell-based therapy clinical trials currently underway. As these stem cell-based therapies become available, NeoStem clients will be among the first to benefit from the life saving progress that has already been made for such debilitating conditions as cancer, heart disease, multiple sclerosis, lupus, and many others.
About NeoStem, Inc.
NeoStem is a biotechnology services company enhancing the delivery of adult stem cell therapeutics to health-conscious consumers. The Company is developing a nationwide network of adult stem cell collection centers, enabling people to donate and store their own stem cells with NeoStem for personal use years or decades later in times of critical medical need.
The proprietary NeoStem technologies empower health-conscious consumers to help protect their future health by undergoing treatment with their own stem-cells - providing an accessible supply of healthy, genetically matched stem cells for use in the eventuality of illness.
Currently underway are hundreds of stem cell-based research programs and clinical trials investigating the use of these non-controversial adult stem cells, such as those collected from donors under NeoStem's methods. As the nation's population ages and encounters serious age-related and congenital health issues, NeoStem has positioned itself as a leader in the fast-growing national trend toward personal "bio-insurance."
The Company's non-capital intensive business plan is a service model that is completely scalable, thus minimizing risk levels ordinarily related to most long-term biopharmaceutical research and development. Under its strategic business plan, NeoStem has begun opening a nationwide network of adult stem cell collection facilities. Its stem cell collection systems will be located in existing physician offices and medical facilities, where the procedures and care can be administered by trusted personal doctors and medical professionals.
For more information, please visit: www.neostem.com.
For other information and resources about the Company, visit www.CFSG1.com or www.trilogy-capital.com/tcp/neostem/quote.html.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the ability of NeoStem, Inc. ("the Company") to develop the adult stem cell business, the future of regenerative medicine and the role of adult stem cells in that future, the future use of adult stem cells as a treatment option and the potential revenue growth of the Company's business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's ability to enter the adult stem cell arena and future operating results are dependent upon many factors, including but not limited to (i) the Company's ability to obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; (iv) scientific and medical developments beyond the Company's control; (v) the Company's inability to obtain appropriate state licenses or any other adverse effect or limitations caused by government regulation of the business; and (vi) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at www.sec.gov under "Search for Company Filings."
Pursuant to an October 1, 2006 agreement, Consulting For Strategic Growth I, Ltd. ("CFSG1") provides the Company with consulting, business advisory, investor relations, public relations and corporate development services, for which CFSG1 receives a fixed monthly fee for the duration of the agreement and received shares of NeoStem's common stock. Independent of CFSG1's receipt of cash or other compensation from the Company, CFSG1 may choose to purchase the common stock of the Company and thereafter sell those shares at any time it deems appropriate to do so. For more information, please visit www.cfsg1.com.
NeoStem, Inc.
Robin Smith, Chief Executive Officer, 212-584-4180
rsmith@neostem.com
www.neostem.com
or
Consulting for Strategic Growth 1
Stanley Wunderlich/Daniel Stepanek, 800-625-2236
Fax: 212-337-8089
http://www.cfsg1.com
or
Financial Communications
Trilogy Capital Partners
Ryon Harms, 800-592-6067
ryon@trilogy-capital.com
Source: Business Wire (August 8, 2007 - 11:01 PM EST)
News by QuoteMedia
www.quotemedia.com
NeoStem Announces Approval for Listing on American Stock Exchange Under Ticker Symbols NBS and NBS.U Starting Thursday August 9, 2007
Concurrent with the Listing, NeoStem Announces Closing of a Public Offering for Over $5 Million and Completes a 1-for-10 Reverse Stock Split
NeoStem, Inc. (OTCBB:NEOI), the first company to specialize in the collection, processing and long term storage of stem cells from healthy adults for personal use in times of critical medical need, today announces its common stock and units have been approved to be listed on the American Stock Exchange under the ticker symbols—NBS and NBS.U—and will start trading August 9, 2007. The listing followed the completion of a public-offering in excess of $5 million and a one-for-ten reverse stock split.
The listing on the American Stock Exchange is consistent with the Company’s strategic mission to attract institutional investors and to provide long-term value for its shareholders.
“We are extremely proud of our recent achievements and of surpassing yet another milestone for the benefit of our shareholders,” said Robin Smith, M.D., Chairman and Chief Executive Officer of NeoStem. “It is an honor to be listed on the American Stock Exchange and to enjoy all the benefits of its long and storied history. We believe these recent developments will be major catalysts as we move forward into a position of leadership in the burgeoning market for stem cell therapies and services.”
The closing of this offering is the latest validation of NeoStem’s high-growth business model focused on developing next generation services and therapies that have the potential to help millions of health-conscious individuals. The total offering comprises units at a price of $5 per unit. Each unit consists of one share of common stock and one-half a Class A warrant to purchase one-half a share of common stock. Thus, 1,000 units consist of 1,000 shares and warrants to purchase 500 shares of common stock.
The Underwriter for the offering was Mercer Capital Ltd., members of the National Association of Securities Dealers, Inc.
NeoStem’s common stock, units and Class A warrants have been accepted for listing on the American Stock Exchange under the symbols “NBS”, “NBS.U”, and “NBS.WS” respectively, effective upon consummation of the initial closing of the offering. The CUSIP for the Common Stock is 640650305, the CUSIP for the Units is 640650206, and the CUSIP for the Warrants is 640650115.
NeoStem’s first-to-market competitive advantage uniquely positions the Company to capitalize on the hundreds of adult stem cell-based therapy clinical trials currently underway. As these stem cell-based therapies become available, NeoStem clients will be among the first to benefit from the life saving progress that has already been made for such debilitating conditions as cancer, heart disease, multiple sclerosis, lupus, and many others.
About NeoStem, Inc.
NeoStem is a biotechnology services company enhancing the delivery of adult stem cell therapeutics to health-conscious consumers. The Company is developing a nationwide network of adult stem cell collection centers, enabling people to donate and store their own stem cells with NeoStem for personal use years or decades later in times of critical medical need.
The proprietary NeoStem technologies empower health-conscious consumers to help protect their future health by undergoing treatment with their own stem-cells - providing an accessible supply of healthy, genetically matched stem cells for use in the eventuality of illness.
Currently underway are hundreds of stem cell-based research programs and clinical trials investigating the use of these non-controversial adult stem cells, such as those collected from donors under NeoStem's methods. As the nation's population ages and encounters serious age-related and congenital health issues, NeoStem has positioned itself as a leader in the fast-growing national trend toward personal "bio-insurance."
The Company's non-capital intensive business plan is a service model that is completely scalable, thus minimizing risk levels ordinarily related to most long-term biopharmaceutical research and development. Under its strategic business plan, NeoStem has begun opening a nationwide network of adult stem cell collection facilities. Its stem cell collection systems will be located in existing physician offices and medical facilities, where the procedures and care can be administered by trusted personal doctors and medical professionals.
For more information, please visit: www.neostem.com.
For other information and resources about the Company, visit www.CFSG1.com or www.trilogy-capital.com/tcp/neostem/quote.html.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the ability of NeoStem, Inc. ("the Company") to develop the adult stem cell business, the future of regenerative medicine and the role of adult stem cells in that future, the future use of adult stem cells as a treatment option and the potential revenue growth of the Company's business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's ability to enter the adult stem cell arena and future operating results are dependent upon many factors, including but not limited to (i) the Company's ability to obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; (iv) scientific and medical developments beyond the Company's control; (v) the Company's inability to obtain appropriate state licenses or any other adverse effect or limitations caused by government regulation of the business; and (vi) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at www.sec.gov under "Search for Company Filings."
Pursuant to an October 1, 2006 agreement, Consulting For Strategic Growth I, Ltd. ("CFSG1") provides the Company with consulting, business advisory, investor relations, public relations and corporate development services, for which CFSG1 receives a fixed monthly fee for the duration of the agreement and received shares of NeoStem's common stock. Independent of CFSG1's receipt of cash or other compensation from the Company, CFSG1 may choose to purchase the common stock of the Company and thereafter sell those shares at any time it deems appropriate to do so. For more information, please visit www.cfsg1.com.
NeoStem, Inc.
Robin Smith, Chief Executive Officer, 212-584-4180
rsmith@neostem.com
www.neostem.com
or
Consulting for Strategic Growth 1
Stanley Wunderlich/Daniel Stepanek, 800-625-2236
Fax: 212-337-8089
http://www.cfsg1.com
or
Financial Communications
Trilogy Capital Partners
Ryon Harms, 800-592-6067
ryon@trilogy-capital.com
Source: Business Wire (August 8, 2007 - 11:01 PM EST)
News by QuoteMedia
www.quotemedia.com
Interesting technology to say the least.
HHDG .005
State the number of shares outstanding of each of the issuer’s classes of common equity, as of the last practicable date.
Outstanding as of June 30, 2007 749,350
Common stock, 750,000,000 shares authorized
Nice post. eom
Do you think you are the only one who has been watching level II? BTW Fagi and cgfl are at .0075 and nite is best ask at .006. CGFL has been showing up on the bid as well.
MACD bullish crossover here as well.
Yep, thought it might have got some action with that PR.
Notice how the PR said that the company has authorized the repurchase up to 500,000$. That means they do not have to buy back any stock if they wish not to. You would think that if it were real they would state something like we will repurchase 200K-500K worth of common stock on the open market or something to give it a little more backbone.
USTG share buyback. Let's see if there is any action.
.064 X .075 1 X 1
WNSH .0007 X .0008 10 X 2
WNSH-5 X.0007 7 X.0008
Some good runners today! eom
It could go either way from here. Level II looks pretty good with 1 at .006 and 2 at .007, bid support is fairly strong. MACD just had a bullish crossover.
CAFE 2.75 15-12G
DYTM 15-12G filed today.
At least we are oversold at this point. There should be some kind of bounce in the next day or two and I would bet Monday, hopefully a trend reversal.
NWMDE .04 filed 15-12G today.
15-12G 1 millineum15.htm UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 000-26493
Millennium National Events, Inc.
(Exact name of registrant as specified in its charter)
1285 Baring Blvd, Box 250
Sparks, NV 89434
(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)
Common Stock, Par Value $0.001 Per Share
(Title of each class of securities covered by this Form)
N/A
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1)(i)
/X/
Rule 12h-3(b)(1)(i)
/ /
Rule 12g-4(a)(1)(ii)
/ /
Rule 12h-3(b)(1)(ii)
/ /
Rule 12g-4(a)(2)(i)
/ /
Rule 12h-3(b)(2)(i)
/ /
Rule 12g-4(a)(2)(ii)
/ /
Rule 12h-3(b)(2)(ii)
/ /
Rule 15d-6
/ /
Approximate number of shareholders of record as of the certificate or notice date: 46
Pursuant to the requirements of the Securities Exchange Act of 1934, Millennium National Events, Inc., a Nevada corporation, has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
Date:
July 12, 2007
By:
Crawford Shaw
President
FVLY 20.45 15-12g filed today.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER
SECTIONS 13 AND 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
COMMISSION FILE NO. 0-51408
FIRST VALLEY BANCORP, INC.
(Exact name of registrant as specified in its charter)
Four Riverside Avenue
Bristol, Connecticut 06010
(Address, including zip code, and telephone number, including area
code, of registrant's principal executive offices)
COMMON STOCK, NO PAR VALUE
(Title of each class of securities covered by this Form)
NONE
(Titles of all other classes of securities for which a duty to file
reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule
provision(s) relied upon to terminate or suspend the duty to file reports:
[X] Rule 12g-4(a)(1)(i) [X] Rule 12h-3(b)(1)(i)
[ ] Rule 12g-4(a)(1)(ii) [ ] Rule 12h-3(b)(1)(ii)
[ ] Rule 12g-4(a)(2)(i) [ ] Rule 12h-3(b)(2)(i)
[ ] Rule 12g-4(a)(2)(ii) [ ] Rule 12h-3(b)(2)(ii)
[ ] Rule 15d-6
Approximate number of holders of record as of the certification or
notice date: 1
Pursuant to the requirements of the Securities Exchange Act of 1934,
New England Bancshares, Inc. has caused this certification/notice to be signed
on its behalf by the undersigned duly authorized person.
DATE: July 13, 2007 By: /s/ David J. O'Connor
--------------------------------------
David J. O'Connor
President and Chief Executive Officer,
New England Bancshares, Inc., as
Successor by Merger
</TEXT>
</DOCUMENT>
1 SHAREHOLDER WTH?
June 26, 2007 - 8:28 AM EST
close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes
FVLY 20.45 0.00
NEBS 12.00 -0.15
Shareholders of First Valley Bancorp, Inc. Approve Merger with New England Bancshares, Inc.
New England Bancshares, Inc. (Nasdaq GM: NEBS) announced that the shareholders of First Valley Bancorp, Inc. (OTCBB: FVLY) overwhelmingly approved the merger of First Valley Bancorp with New England Bancshares at a meeting held June 25. All required regulatory approvals have also been obtained. The parties anticipate closing the transaction in July.
New England Bancshares, Inc. is the holding company for Enfield Federal Savings and Loan Association. Enfield Federal Savings and Loan Association operates eight banking centers serving the communities of Enfield, Ellington, Manchester, Suffield, East Windsor and Windsor Locks, Connecticut. At March 31, 2007, New England Bancshares had total assets of $284.2 million.
First Valley Bancorp, Inc. is the holding company for Valley Bank. Valley Bank operates four offices in Bristol, Terryville and Southington, Connecticut. At March 31, 2007, First Valley Bancorp had total assets of $184.9 million.
New England Bancshares, Inc.
David J. O’Connor, 860-253-5200
President and Chief Executive Officer
Source: Business Wire (June 26, 2007 - 8:28 AM EST)
News by QuoteMedia
Well I have seen just about enough of this nonsense. I have played this game too long to see this happen again. Such a fool am I for holding. I once thought you could invest in a penny and if you found the right one you could make a fortune. I actually had a long lost uncle that did just this but that was a long time ago.
I traded this three times in the recent past and made money each time just watching level II and the tape. Now for some stupid reason I have bought in and not sold but averaged down and it still keeps going down.
I do not care what anyone else says. The market makers that are there now are not the ones that were there before on the ask. END OF STORY. My gut told me this along with a little common sense but I did not listen.
Now I am down well over 50 percent and I swore I would never let that happen again. A trade that became a freakin bagholder is what I am here. Stupidity to say the least. I have worked to hard to watch my portfolio go up so nicely and then to sit here like a dumbass because I believe in NORRIS who I have never met and watch a big loss occur before my eyes.
How long does it take for one to truly understand that pinks and even OTCBB are strictly for trading and trading only!!!!!!!!!!!!!!!!!!
Obviously I am a slow learner.
Good to hear from you buytex. I'm just lurking around here as usual and fixin to head to work.
Shocker, you mean to tell me you can't give your word when a penny will take off.
AWWW man, you just fell off the pedestal I have held you one for so long.
That's OK JJ, you still the man. LOL
And I already had your new website ready.
JJ's pennies-when I say they are ready they
BLYC-.001 filed 15-12g today. Last PR spoke of an acquistion. Might be a reverse merger soon, who knows.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=5045841</a>" target="_blank">http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=5045841">http://xml.10kwizard.co...
OPLM-DEFM14a filed today. Not really a reverse merger but might as well be. Company will keep its name and RS and will acquire a private company. One to watch.
IEIB 6.63 15-12g filed today. Not really a penny but one to watch.
I hope you are right, but the new MM's on the ask are strange to say the least.
I agree with the comments about Norris in particular, that is why I am here.
Faith in the man in charge.
My last post was to the wrong board, thus the deleted message.
The OS has increased significantly in the last six months. What more does one need?
Yes, it appears they have acquired some good things with the shares and maybe it will pay off, but the dilution must stop at some point.
Do not buy or sell because of my comments, I have no agenda here whatsoever other than for the truth to be told.
I bought in at .0003 and made a good profit here and hope the company goes on to excel, and hopefully I can time it correctly to get back in and join the ride back up.
Done posting here for a while but will be watching. I hope all you guys the best.
Let's be honest here. Do you think the PPS might go up if the company would quit selling shares? Compare the OS now to what is was 6 months ago. I like the company just as much as you guys do but for heaven's sake the PPS can't rise much with the dilution. The only thing that is keeping this thing from going to .0001 is because they are real and do have operations. There is alot of interest in this company.
You would think they could come up with some capital with a private placement or something but it appears that selling shares is their way at this point.
I sold out a little while back and will buy back in when they quit selling shares if I can determine that, a tough thing to do for sure.
Good luck to all.